Comparison of participants to eligible nonparticipants
| . | Participants, n = 92 . | Eligible nonparticipants, n = 127 . | P . |
|---|---|---|---|
| Mean age at diagnosis, y (SD) | 3.3 (1.2) | 3.1 (1.1) | .23 |
| Mean years between diagnosis and start of the study (SD) | 9.8 (0.6) | 9.8 (0.6) | .93 |
| Sex, no. (%) | |||
| Female | 51(55.4) | 64 (50.4) | .46 |
| Male | 41(44.6) | 63 (49.6) | |
| Corticosteroid therapy, no. (%) | |||
| Dexamethasone | 51(55.4) | 63 (49.6) | .39 |
| Prednisone | 41(44.6) | 64 (50.4) | |
| 6-Mercaptopurine therapy, no. (%) | |||
| Oral | 47 (50.5) | 69 (54.3) | .64 |
| Intravenous | 45 (49.5) | 58 (45.7) |
| . | Participants, n = 92 . | Eligible nonparticipants, n = 127 . | P . |
|---|---|---|---|
| Mean age at diagnosis, y (SD) | 3.3 (1.2) | 3.1 (1.1) | .23 |
| Mean years between diagnosis and start of the study (SD) | 9.8 (0.6) | 9.8 (0.6) | .93 |
| Sex, no. (%) | |||
| Female | 51(55.4) | 64 (50.4) | .46 |
| Male | 41(44.6) | 63 (49.6) | |
| Corticosteroid therapy, no. (%) | |||
| Dexamethasone | 51(55.4) | 63 (49.6) | .39 |
| Prednisone | 41(44.6) | 64 (50.4) | |
| 6-Mercaptopurine therapy, no. (%) | |||
| Oral | 47 (50.5) | 69 (54.3) | .64 |
| Intravenous | 45 (49.5) | 58 (45.7) |